KPV, Inflammation and the Research
If one word ties this blend together, it is inflammation. It is the body’s first response to damage or infection: blood flow rises, immune cells rush in and the area swells. That is helpful for a while. When it lingers, it can damage the lining of the gut, irritate skin and get in the way of healing. KPV was added to this mix because nearly all of its research is about switching that response down.
What KPV Brings
- The first clue (FASEB J, 1989): in mice, the KPV fragment reduced chemically triggered ear swelling, showing that a piece of alpha-MSH could calm inflammation by itself.
- Inside immune cells (Biochem Pharmacol, 2001): in mouse macrophages, KPV lowered nitric oxide output and blocked NF-κB, a key inflammation switch, without binding the receptor that alpha-MSH uses for pigment.
- The eye surface (Exp Eye Res, 2006): in rabbits with scraped corneas, eye drops with KPV helped the surface layer grow back faster than drops without it.
- A doorway into gut cells (Gastroenterology, 2008): KPV entered intestinal and immune cells through the PepT1 transporter and reduced inflammatory signals; mice given KPV by mouth developed milder colitis.
- Two colitis models (Inflamm Bowel Dis, 2008): mice treated with KPV recovered weight sooner and showed fewer inflammatory cells in the colon.
- The bigger picture (Endocr Rev, 2008): a review of alpha-MSH and its tiny fragments as possible future treatments for immune-driven inflammation.
- Delivery experiments (Mol Ther, 2017, and Biomater Sci, 2021): KPV packed into nanoparticles or a sticky gel reduced colitis in mice and helped mouth sores caused by chemotherapy in an animal model.
- Skin and wounds (Exp Dermatol, 2019): a review asking whether alpha-MSH-type peptides could one day help skin wounds heal.
The Other Three Through the Same Lens
GHK-Cu, BPC-157 and TB-500 are usually described as repair peptides. Interestingly, each also has a few studies pointing in the same anti-inflammatory direction as KPV.
- BPC-157 in the colon (J Physiol Pharmacol, 2013): in rats, it helped heal chemically induced colitis and surgical joins in the bowel.
- BPC-157 and the gut–brain link (Curr Neuropharmacol, 2016): a review from the Zagreb group on the peptide’s role along the gut–brain axis.
- Thymosin beta-4 on the cornea (Exp Eye Res, 2007): in human corneal cells, it held back NF-κB activation triggered by an inflammatory signal.
- Thymosin beta-4 overview (Expert Opin Biol Ther, 2012): a summary of its many roles, from cell movement to dampening inflammation.
- GHK-Cu and skin cells (Acta Pol Pharm, 2012): copper peptides including GHK-Cu lowered release of the inflammatory messenger IL-6 in human skin fibroblasts.
- GHK-Cu in the lungs (Oncotarget, 2016): in mice with induced lung injury, it reduced inflammatory cells and signals.
How the Four-Part Idea Hangs Together
On paper, the reasoning runs like this. GHK-Cu, BPC-157 and TB-500 are linked to the rebuilding side of healing, while KPV is linked to keeping inflammation in check, especially in the gut and skin. Because the first three also show some calming effects, the overlap could, in theory, be useful. It could equally turn out to make little difference. That is a question for a properly designed study, not for a product label.
What Has Not Been Shown
- Any combined study: no paper has tested KPV together with GHK-Cu, BPC-157 or TB-500.
- Results in people: KPV has no published human trials, and the human data for the other three are sparse.
- How it reaches the body: the gut studies of KPV relied on special transporters or delivery systems, which a simple powder does not reproduce.
- Interactions: four peptides in one solution could compete, break down faster or behave unpredictably.
The Takeaway
KPV is the most distinctive part of KLOW, backed by a small but consistent set of animal and cell studies on inflammation. The case for the full four-part mix, however, rests on logic rather than data.
References
- Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989;3(11):2282-2284. PMID 2550304
- Mandrika I, Muceniece R, Wikberg JE. Effects of melanocortin peptides on lipopolysaccharide/interferon-gamma-induced NF-kappaB DNA binding and nitric oxide production in macrophage-like RAW 264.7 cells: evidence for dual mechanisms of action. Biochem Pharmacol. 2001;61(5):613-621. PMID 11239505
- Bonfiglio V, et al. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res. 2006;83(6):1366-1372. PMID 16965771
- Sosne G, et al. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res. 2007;84(4):663-669. PMID 17254567
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID 18061177
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. PMID 18092346
- Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. PMID 18612139
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PMID 22074294
- Gruchlik A, et al. Effect of Gly-Gly-His, Gly-His-Lys and their copper complexes on TNF-alpha-dependent IL-6 secretion in normal human dermal fibroblasts. Acta Pol Pharm. 2012;69(6):1303-1306. PMID 23285694
- Klicek R, et al. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. J Physiol Pharmacol. 2013;64(5):597-612. PMID 24304574
- Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID 27138887
- Park JR, et al. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget. 2016;7(36):58405-58417. PMID 27517151
- Xiao B, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25(7):1628-1640. PMID 28143741
- Böhm M, Luger T. Are melanocortin peptides future therapeutics for cutaneous wound healing? Exp Dermatol. 2019;28(3):219-224. PMID 30661264
- Shao W, et al. In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis. Biomater Sci. 2021;10(1):227-242. PMID 34846053